Axiom Advisory’s AbbVie ABBV Stock Holding History

Axiom Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$4.4M	Buy	23,552 +522	+2%	+$97.4K	0.04%	63
2024 Q2	$3.81M	Buy	+23,030	New	+$3.81M	0.04%	68

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Axiom Advisory's ABBV Position: Q3 2024 in Review

Axiom Advisory increased its AbbVie (ABBV) stake by 2.3% in Q3 2024, buying an estimated $97.4K and bringing the position to 23,552 shares worth $4.4M. The position accounts for 0.04% of the portfolio, ranked #63.

Axiom Advisory first reported a position in ABBV in Q2 2024 and has held it in 2 quarters since. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Axiom Advisory held 23,552 shares of AbbVie worth $4.4M as of Q3 2024.
Axiom Advisory bought 522 AbbVie shares in Q3 2024, an estimated $97.4K.
AbbVie made up 0.04% of Axiom Advisory's portfolio in Q3 2024, its #63 holding.
Axiom Advisory first reported a position in AbbVie in Q2 2024 and has held it in 2 quarters since.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Axiom Advisory's 13F filing for Q3 2024, filed 7 Oct 2024.